Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,349 active trials259 approved drugs3,859 evidence items
- NCIt
- C7062
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,726 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06333951 | Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104). | active not recruiting | Phase 1 | 49 | AmgenINDUSTRY | 20 | May 28, 2026 | clinicaltrials |
| NCT02159755 | Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma | active not recruiting | Phase 1 | 28 | National Cancer Institute (NCI)NIH | 1 | May 27, 2026 | clinicaltrials |
| NCT05806814 | Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer(OU-SCC-EXCITE) | active not recruiting | Phase 1 | 15 | University of OklahomaOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT07422805 | Circulating Tumor DNA in Melanoma Patients(ctDNA) | active not recruiting | Phase 1 / Phase 2 | 176 | Institute of Oncology LjubljanaOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT03598998 | Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas | active not recruiting | Phase 1 / Phase 2 | 13 | City of Hope Medical CenterOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT04250545 | Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer | active not recruiting | Phase 1 | 22 | National Cancer Institute (NCI)NIH | 1 | May 26, 2026 | clinicaltrials |
| NCT04588545 | Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease | active not recruiting | Phase 1 / Phase 2 | 33 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT04731376 | Perioperative Testosterone Replacement Therapy for the Improvement of Post-Operative Outcomes in Patients With Low Testosterone | active not recruiting | Phase 1 | 56 | Emory UniversityOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT01251874 | Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer | active not recruiting | Phase 1 | 44 | National Cancer Institute (NCI)NIH | 1 | May 22, 2026 | clinicaltrials |
| NCT02632708 | Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation | active not recruiting | Phase 1 | 153 | Institut de Recherches Internationales ServierOTHER | 3 | May 22, 2026 | clinicaltrials |
| NCT03172754 | Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma | active not recruiting | Phase 1 / Phase 2 | 98 | Fox Chase Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT04484909 | NBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic Cancer | active not recruiting | Phase 1 | 24 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT05682443 | ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC(PRESERVE-006) | active not recruiting | Phase 1 / Phase 2 | 148 | OncoC4, Inc.INDUSTRY | 1 | May 22, 2026 | clinicaltrials |
| NCT05736406 | A Dose-escalation Clinical Study of Intraoperative Photodynamic Therapy of Glioblastoma | active not recruiting | Phase 1 / Phase 2 | 12 | Hemerion TherapeuticsINDUSTRY | 2 | May 22, 2026 | clinicaltrials |
| NCT06238479 | A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors(EXCEED) | active not recruiting | Phase 1 | 490 | Eli Lilly and CompanyINDUSTRY | 7 | May 22, 2026 | clinicaltrials |
| NCT02321501 | Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer | active not recruiting | Phase 1 | 37 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT02696993 | Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer | active not recruiting | Phase 1 / Phase 2 | 80 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT03613532 | Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN | active not recruiting | Phase 1 | 102 | Jacqueline Garcia, MDOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT04388852 | DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers | active not recruiting | Phase 1 | 65 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT05546879 | Study Investigating the Association of NP137 With Atezolizumab-Bevacizumab Combination in First Line in Unresectable HCC(Liver-NET1) | active not recruiting | Phase 1 | 43 | University Hospital, GrenobleOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT06898957 | Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)((DeLLphi-310)) | active not recruiting | Phase 1 | 29 | AmgenINDUSTRY | 10 | May 20, 2026 | clinicaltrials |
| NCT07587619 | Intraoperative Use of Oxygen Saturation Imaging to Assess Intestinal Perfusion | active not recruiting | Phase 1 / Phase 2 | 52 | University of Southern CaliforniaOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT02311621 | Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01 | active not recruiting | Phase 1 | 65 | Seattle Children's HospitalOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT07280377 | A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab(GOBLET) | active not recruiting | Phase 1 / Phase 2 | 122 | Oncolytics BiotechINDUSTRY | 1 | May 19, 2026 | clinicaltrials |
| NCT02797470 | Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant | active not recruiting | Phase 1 / Phase 2 | 11 | AIDS Malignancy ConsortiumNETWORK | 1 | May 18, 2026 | clinicaltrials |
| NCT03386500 | Safety Study of BMX-001 (Radio-protector) in Patients With Newly Diagnosed Anal Cancer | active not recruiting | Phase 1 / Phase 2 | 24 | University of NebraskaOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT04661007 | To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)(J-MIND) | active not recruiting | Phase 1 / Phase 2 | 72 | Incyte Biosciences Japan GKINDUSTRY | 1 | May 18, 2026 | clinicaltrials |
| NCT05678010 | A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer | active not recruiting | Phase 1 | 54 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT06724926 | Concurrent Azeliragon With Craniospinal Irradiation | active not recruiting | Phase 1 | 21 | NYU Langone HealthOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT02334865 | SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy | active not recruiting | Phase 1 | 18 | Roswell Park Cancer InstituteOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT03611738 | Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC | active not recruiting | Phase 1 | 21 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT04137536 | A Study of Armed, Activated T-Cells in Patients With Advanced Pancreatic Cancer | active not recruiting | Phase 1 | 7 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT04526691 | Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02) | active not recruiting | Phase 1 | 145 | Daiichi SankyoINDUSTRY | 5 | May 15, 2026 | clinicaltrials |
| NCT05462717 | Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors | active not recruiting | Phase 1 | 222 | Revolution Medicines, Inc.INDUSTRY | 13 | May 15, 2026 | clinicaltrials |
| NCT05653752 | A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer | active not recruiting | Phase 1 | 80 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 2 | May 15, 2026 | clinicaltrials |
| NCT01947023 | Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery | active not recruiting | Phase 1 | 23 | National Cancer Institute (NCI)NIH | 1 | May 14, 2026 | clinicaltrials |
| NCT03598595 | Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma | active not recruiting | Phase 1 / Phase 2 | 31 | M.D. Anderson Cancer CenterOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT03807778 | A Study of Mobocertinib in Japanese Adults With Non-Small Cell Lung Cancer | active not recruiting | Phase 1 | 53 | TakedaINDUSTRY | 1 | May 14, 2026 | clinicaltrials |
| NCT04003649 | IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM | active not recruiting | Phase 1 | 20 | City of Hope Medical CenterOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT04477200 | Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma | active not recruiting | Phase 1 | 68 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT01955499 | Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | active not recruiting | Phase 1 | 39 | National Cancer Institute (NCI)NIH | 2 | May 13, 2026 | clinicaltrials |
| NCT04067336 | First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia | active not recruiting | Phase 1 / Phase 2 | 263 | Kura Oncology, Inc.INDUSTRY | 7 | May 13, 2026 | clinicaltrials |
| NCT05002816 | Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma | active not recruiting | Phase 1 / Phase 2 | 24 | Yale UniversityOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT05353439 | Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer | active not recruiting | Phase 1 | 18 | National Cancer Institute (NCI)NIH | 1 | May 13, 2026 | clinicaltrials |
| NCT05514990 | Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial | active not recruiting | Phase 1 / Phase 2 | 10 | University of Southern CaliforniaOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT05691504 | Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers | active not recruiting | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | May 13, 2026 | clinicaltrials |
| NCT05981209 | Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies | active not recruiting | Phase 1 | 12 | Abdullah KhanOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT02998567 | Combination Study of Guadecitabine/ASTX727 and Pembrolizumab(HyPeR) | active not recruiting | Phase 1 | 60 | Royal Marsden NHS Foundation TrustOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT03819465 | A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC(MAGELLAN) | active not recruiting | Phase 1 | 175 | AstraZenecaINDUSTRY | 9 | May 12, 2026 | clinicaltrials |
| NCT04150887 | Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia(ELEVATE) | active not recruiting | Phase 1 | 61 | OncoVerity, Inc.INDUSTRY | 5 | May 12, 2026 | clinicaltrials |
Data updated 23 days agoSource updated May 28, 2026source: clinicaltrials